Due to toxicity and compliance issues and the emergence of resistance to current medications new drugs for the treatment of Human African Trypanosomiasis are needed. A potential approach to developing novel anti-trypanosomal drugs is by inhibition of the 6-oxopurine salvage pathways which synthesise the nucleoside monophosphates required for DNA/RNA production. This is in view of the fact that trypanosomes lack the machinery for de novo synthesis of the purine ring. To provide validation for this approach as a drug target, we have RNAi silenced the three 6-oxopurine phosphoribosyltransferase (PRTase) isoforms in the infectious stage of Trypanosoma brucei demonstrating that the combined activity of these enzymes is critical for the parasites' viability. Furthermore, we have determined crystal structures of two of these isoforms in complex with several acyclic nucleoside phosphonates (ANPs), a class of compound previously shown to inhibit 6-oxopurine PRTases from several species including Plasmodium falciparum. The most potent of these compounds have Ki values as low as 60 nM, and IC50 values in cell based assays as low as 4 μM. This data provides a solid platform for further investigations into the use of this pathway as a target for anti-trypanosomal drug discovery.

Faculty of Science University of South Bohemia Branišovská České Budějovice Czech Republic

Institute of Parasitology Biology Centre Czech Academy of Sciences Branišovská České Budějovice Czech Republic

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Flemingovo nám Prague Czech Republic

The School of Chemistry and Molecular Biosciences The University of Queensland Brisbane QLD Australia

Zobrazit více v PubMed

Simarro PP, Cecchi G, Franco JR, Paone M, Diarra A, et al. (2012) Estimating and mapping the population at risk of sleeping sickness. PLoS Negl Trop Dis 6: e1859 doi: 10.1371/journal.pntd.0001859 PubMed DOI PMC

Simarro PP, Diarra A, Ruiz Postigo JA, Franco JR, Jannin JG (2011) The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000–2009: the way forward. PLoS Negl Trop Dis 5: e1007 doi: 10.1371/journal.pntd.0001007 PubMed DOI PMC

WHO (2013) Control and surveillance of human African trypanosomiasis. World Health Organ Tech Rep Ser 984: 1–237. PubMed

Nagle AS, Khare S, Kumar AB, Supek F, Buchynskyy A, et al. (2014) Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. Chem Rev 114: 11305–11347. doi: 10.1021/cr500365f PubMed DOI PMC

Graf FE, Ludin P, Arquint C, Schmidt RS, Schaub N, et al. (2016) Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense. Cell Mol Life Sci 73: 3387–3400. doi: 10.1007/s00018-016-2173-6 PubMed DOI PMC

Barrett MP, Vincent IM, Burchmore RJ, Kazibwe AJ, Matovu E (2011) Drug resistance in human African trypanosomiasis. Future Microbiol 6: 1037–1047. doi: 10.2217/fmb.11.88 PubMed DOI

Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, et al. (2005) The genome of the African trypanosome Trypanosoma brucei. Science 309: 416–422. doi: 10.1126/science.1112642 PubMed DOI

El-Sayed NM, Myler PJ, Blandin G, Berriman M, Crabtree J, et al. (2005) Comparative genomics of trypanosomatid parasitic protozoa. Science 309: 404–409. doi: 10.1126/science.1112181 PubMed DOI

Van Rompay AR, Johansson M, Karlsson A (2000) Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol Ther 87: 189–198. PubMed

Allen TE, Ullman B (1993) Cloning and expression of the hypoxanthine-guanine phosphoribosyltransferase gene from Trypanosoma brucei. Nucleic Acids Res 21: 5431–5438. PubMed PMC

Eakin AE, Nieves-Alicea R, Tosado-Acevedo R, Chin MS, Wang CC, et al. (1995) Comparative complement selection in bacteria enables screening for lead compounds targeted to a purine salvage enzyme of parasites. Antimicrob Agents Chemother 39: 620–625. PubMed PMC

de Jersey J, Holy A, Hockova D, Naesens L, Keough DT, et al. (2011) 6-oxopurine phosphoribosyltransferase: a target for the development of antimalarial drugs. Curr Top Med Chem 11: 2085–2102. PubMed

Canyuk B, Medrano FJ, Wenck MA, Focia PJ, Eakin AE, et al. (2004) Interactions at the dimer interface influence the relative efficiencies for purine nucleotide synthesis and pyrophosphorolysis in a phosphoribosyltransferase. J Mol Biol 335: 905–921. PubMed

Craig SP 3rd, Eakin AE (1997) Purine salvage enzymes of parasites as targets for structure-based inhibitor design. Parasitol Today 13: 238–241. PubMed

Fernandez D, Wenck MA, Craig SP 3rd, Delfino JM (2004) The purine transferase from Trypanosoma cruzi as a potential target for bisphosphonate-based chemotherapeutic compounds. Bioorg Med Chem Lett 14: 4501–4504. doi: 10.1016/j.bmcl.2004.06.042 PubMed DOI

Teran D, Hockova D, Cesnek M, Zikova A, Naesens L, et al. (2016) Crystal structures and inhibition of Trypanosoma brucei hypoxanthine-guanine phosphoribosyltransferase. Sci Rep 6: 35894 doi: 10.1038/srep35894 PubMed DOI PMC

Berg M, Van der Veken P, Goeminne A, Haemers A, Augustyns K (2010) Inhibitors of the purine salvage pathway: a valuable approach for antiprotozoal chemotherapy? Curr Med Chem 17: 2456–2481. PubMed

De Clercq E (2013) Highlights in antiviral drug research: antivirals at the horizon. Med Res Rev 33: 1215–1248. doi: 10.1002/med.21256 PubMed DOI PMC

Keough DT, Hockova D, Holy A, Naesens LM, Skinner-Adams TS, et al. (2009) Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics. J Med Chem 52: 4391–4399. doi: 10.1021/jm900267n PubMed DOI

Ducati RG, Breda A, Basso LA, Santos DS (2011) Purine Salvage Pathway in Mycobacterium tuberculosis. Curr Med Chem 18: 1258–1275. PubMed

Keough DT, Spacek P, Hockova D, Tichy T, Vrbkova S, et al. (2013) Acyclic nucleoside phosphonates containing a second phosphonate group are potent inhibitors of 6-oxopurine phosphoribosyltransferases and have antimalarial activity. J Med Chem 56: 2513–2526. doi: 10.1021/jm301893b PubMed DOI

Cesnek M, Hockova D, Holy A, Dracinsky M, Baszczynski O, et al. (2012) Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases. Bioorg Med Chem 20: 1076–1089. doi: 10.1016/j.bmc.2011.11.034 PubMed DOI

Hockova D, Keough DT, Janeba Z, Wang TH, de Jersey J, et al. (2012) Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases. J Med Chem 55: 6209–6223. doi: 10.1021/jm300662d PubMed DOI

De Clercq E, Holy A (2005) Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 4: 928–940. doi: 10.1038/nrd1877 PubMed DOI

Keough DT, Hockova D, Krecmerova M, Cesnek M, Holy A, et al. (2010) Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase: a target for anti-malarial chemotherapy. Mol Biochem Parasitol 173: 165–169. doi: 10.1016/j.molbiopara.2010.05.018 PubMed DOI

Keough DT, Hockova D, Rejman D, Spacek P, Vrbkova S, et al. (2013) Inhibition of the Escherichia coli 6-oxopurine phosphoribosyltransferases by nucleoside phosphonates: potential for new antibacterial agents. J Med Chem 56: 6967–6984. doi: 10.1021/jm400779n PubMed DOI

Krecmerova M, Dracinsky M, Hockova D, Holy A, Keough DT, et al. (2012) Synthesis of purine N9-[2-hydroxy-3-O-(phosphonomethoxy)propyl] derivatives and their side-chain modified analogs as potential antimalarial agents. Bioorg Med Chem 20: 1222–1230. doi: 10.1016/j.bmc.2011.12.034 PubMed DOI

Eng WS, Hockova D, Spacek P, Janeba Z, West NP, et al. (2015) First Crystal Structures of Mycobacterium tuberculosis 6-Oxopurine Phosphoribosyltransferase: Complexes with GMP and Pyrophosphate and with Acyclic Nucleoside Phosphonates Whose Prodrugs Have Antituberculosis Activity. J Med Chem 58: 4822–4838. doi: 10.1021/acs.jmedchem.5b00611 PubMed DOI

Keough DT, Hockova D, Janeba Z, Wang TH, Naesens L, et al. (2015) Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their prodrugs as antimalarial agents. J Med Chem 58: 827–846. doi: 10.1021/jm501416t PubMed DOI

Hockova D, Janeba Z, Naesens L, Edstein MD, Chavchich M, et al. (2015) Antimalarial activity of prodrugs of N-branched acyclic nucleoside phosphonate inhibitors of 6-oxopurine phosphoribosyltransferases. Bioorg Med Chem 23: 5502–5510. doi: 10.1016/j.bmc.2015.07.038 PubMed DOI

Oliveira FM BL, Ismail FM (2014) The diverse pharmacology and medicinal chemistry of phosphoramidates–a review. RSC Advances 4: 18998–19012.

Wirtz E, Leal S, Ochatt C, Cross GA (1999) A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol Biochem Parasitol 99: 89–101. PubMed

Creek DJ, Nijagal B, Kim DH, Rojas F, Matthews KR, et al. (2013) Metabolomics guides rational development of a simplified cell culture medium for drug screening against Trypanosoma brucei. Antimicrob Agents Chemother 57: 2768–2779. doi: 10.1128/AAC.00044-13 PubMed DOI PMC

Wickstead B, Ersfeld K, Gull K (2002) Targeting of a tetracycline-inducible expression system to the transcriptionally silent minichromosomes of Trypanosoma brucei. Mol Biochem Parasitol 125: 211–216. PubMed

Flaspohler JA, Jensen BC, Saveria T, Kifer CT, Parsons M (2010) A novel protein kinase localized to lipid droplets is required for droplet biogenesis in trypanosomes. Eukaryot Cell 9: 1702–1710. doi: 10.1128/EC.00106-10 PubMed DOI PMC

Hannaert V, Albert MA, Rigden DJ, da Silva Giotto MT, Thiemann O, et al. (2003) Kinetic characterization, structure modelling studies and crystallization of Trypanosoma brucei enolase. Eur J Biochem 270: 3205–3213. PubMed

Panigrahi AK, Zikova A, Dalley RA, Acestor N, Ogata Y, et al. (2008) Mitochondrial complexes in Trypanosoma brucei: a novel complex and a unique oxidoreductase complex. Mol Cell Proteomics 7: 534–545. doi: 10.1074/mcp.M700430-MCP200 PubMed DOI

Keough DT, Ng AL, Winzor DJ, Emmerson BT, de Jersey J (1999) Purification and characterization of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase and comparison with the human enzyme. Mol Biochem Parasitol 98: 29–41. PubMed

Keough DT, Ng AL, Emmerson BT, de Jersey J (1998) Expression and properties of recombinant P. falciparum hypoxanthine-guanine phosphoribosyltransferase. Adv Exp Med Biol 431: 735–739. PubMed

McPhillips TM, McPhillips SE, Chiu HJ, Cohen AE, Deacon AM, et al. (2002) Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. J Synchrotron Radiat 9: 401–406. PubMed

Kabsch W (2010) Xds. Acta Crystallogr D Biol Crystallogr 66: 125–132. doi: 10.1107/S0907444909047337 PubMed DOI PMC

McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658–674. doi: 10.1107/S0021889807021206 PubMed DOI PMC

Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213–221. doi: 10.1107/S0907444909052925 PubMed DOI PMC

Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66: 486–501. doi: 10.1107/S0907444910007493 PubMed DOI PMC

Allen T, Henschel EV, Coons T, Cross L, Conley J, et al. (1989) Purification and characterization of the adenine phosphoribosyltransferase and hypoxanthine-guanine phosphoribosyltransferase activities from Leishmania donovani. Mol Biochem Parasitol 33: 273–281. PubMed

Hammond DJ, Gutteridge WE (1984) Purine and pyrimidine metabolism in the Trypanosomatidae. Mol Biochem Parasitol 13: 243–261. PubMed

Chen Y, Hung CH, Burderer T, Lee GS (2003) Development of RNA interference revertants in Trypanosoma brucei cell lines generated with a double stranded RNA expression construct driven by two opposing promoters. Mol Biochem Parasitol 126: 275–279. PubMed

Shi W, Li CM, Tyler PC, Furneaux RH, Cahill SM, et al. (1999) The 2.0 A structure of malarial purine phosphoribosyltransferase in complex with a transition-state analogue inhibitor. Biochemistry 38: 9872–9880. doi: 10.1021/bi990664p PubMed DOI

Heroux A, White EL, Ross LJ, Borhani DW (1999) Crystal structures of the Toxoplasma gondii hypoxanthine-guanine phosphoribosyltransferase-GMP and -IMP complexes: comparison of purine binding interactions with the XMP complex. Biochemistry 38: 14485–14494. PubMed

Monzani PS, Trapani S, Thiemann OH, Oliva G (2007) Crystal structure of Leishmania tarentolae hypoxanthine-guanine phosphoribosyltransferase. BMC Struct Biol 7: 59 doi: 10.1186/1472-6807-7-59 PubMed DOI PMC

Focia PJ, Craig SP 3rd, Nieves-Alicea R, Fletterick RJ, Eakin AE (1998) A 1.4 A crystal structure for the hypoxanthine phosphoribosyltransferase of Trypanosoma cruzi. Biochemistry 37: 15066–15075. doi: 10.1021/bi981052s PubMed DOI

Boitz JM, Ullman B, Jardim A, Carter NS (2012) Purine salvage in Leishmania: complex or simple by design? Trends Parasitol 28: 345–352. doi: 10.1016/j.pt.2012.05.005 PubMed DOI PMC

Li Q, Leija C, Rijo-Ferreira F, Chen J, Cestari I, et al. (2015) GMP synthase is essential for viability and infectivity of Trypanosoma brucei despite a redundant purine salvage pathway. Mol Microbiol 97: 1006–1020. doi: 10.1111/mmi.13083 PubMed DOI PMC

Hazleton KZ, Ho MC, Cassera MB, Clinch K, Crump DR, et al. (2012) Acyclic immucillin phosphonates: second-generation inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase. Chem Biol 19: 721–730. doi: 10.1016/j.chembiol.2012.04.012 PubMed DOI PMC

Boitz JM, Ullman B (2006) A conditional mutant deficient in hypoxanthine-guanine phosphoribosyltransferase and xanthine phosphoribosyltransferase validates the purine salvage pathway of Leishmania donovani. J Biol Chem 281: 16084–16089. doi: 10.1074/jbc.M600188200 PubMed DOI

Mony BM, MacGregor P, Ivens A, Rojas F, Cowton A, et al. (2014) Genome-wide dissection of the quorum sensing signalling pathway in Trypanosoma brucei. Nature 505: 681–685. doi: 10.1038/nature12864 PubMed DOI PMC

Keough DT, Brereton IM, de Jersey J, Guddat LW (2005) The crystal structure of free human hypoxanthine-guanine phosphoribosyltransferase reveals extensive conformational plasticity throughout the catalytic cycle. J Mol Biol 351: 170–181. doi: 10.1016/j.jmb.2005.05.061 PubMed DOI

Guddat LW, Vos S, Martin JL, Keough DT, de Jersey J (2002) Crystal structures of free, IMP-, and GMP-bound Escherichia coli hypoxanthine phosphoribosyltransferase. Protein Sci 11: 1626–1638. doi: 10.1110/ps.0201002 PubMed DOI PMC

Page T, Bakay B, Nissinen E, Nyhan WL (1981) Hypoxanthine-guanine phosphoribosyltransferase variants: correlation of clinical phenotype with enzyme activity. J Inherit Metab Dis 4: 203–206. PubMed

Development of Prolinol Containing Inhibitors of Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase: Rational Structure-Based Drug Design

Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects

Acyclic nucleoside phosphonates with adenine nucleobase inhibit Trypanosoma brucei adenine phosphoribosyltransferase in vitro